Form 8-K - Current report:
SEC Accession No. 0001437749-23-018677
Filing Date
2023-06-28
Accepted
2023-06-28 09:01:44
Documents
14
Period of Report
2023-06-27
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K atos20230627_8k.htm   iXBRL 8-K 26419
2 EXHIBIT 99.1 ex_538897.htm EX-99.1 7912
  Complete submission text file 0001437749-23-018677.txt   169902

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atos-20230627.xsd EX-101.SCH 3409
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE atos-20230627_def.xml EX-101.DEF 11424
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE atos-20230627_lab.xml EX-101.LAB 15310
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atos-20230627_pre.xml EX-101.PRE 11584
8 EXTRACTED XBRL INSTANCE DOCUMENT atos20230627_8k_htm.xml XML 2549
Mailing Address 107 SPRING STREET SEATTLE WA 98104
Business Address 107 SPRING STREET SEATTLE WA 98104 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35610 | Film No.: 231049506
SIC: 2834 Pharmaceutical Preparations